Perspective Therapeutics (CATX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$321.5 million.
- Perspective Therapeutics' Enterprise Value fell 396.86% to -$321.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$321.5 million, marking a year-over-year decrease of 396.86%. This contributed to the annual value of -$226.9 million for FY2024, which is 235633.25% down from last year.
- According to the latest figures from Q3 2025, Perspective Therapeutics' Enterprise Value is -$321.5 million, which was down 396.86% from -$354.3 million recorded in Q2 2025.
- Perspective Therapeutics' 5-year Enterprise Value high stood at -$9.2 million for Q4 2023, and its period low was -$379.0 million during Q1 2025.
- In the last 5 years, Perspective Therapeutics' Enterprise Value had a median value of -$61.7 million in 2021 and averaged -$137.9 million.
- As far as peak fluctuations go, Perspective Therapeutics' Enterprise Value tumbled by 307989.69% in 2021, and later skyrocketed by 7888.79% in 2023.
- Perspective Therapeutics' Enterprise Value (Quarter) stood at -$60.4 million in 2021, then rose by 27.5% to -$43.8 million in 2022, then surged by 78.89% to -$9.2 million in 2023, then crashed by 2356.33% to -$226.9 million in 2024, then tumbled by 41.67% to -$321.5 million in 2025.
- Its Enterprise Value was -$321.5 million in Q3 2025, compared to -$354.3 million in Q2 2025 and -$379.0 million in Q1 2025.